RxDoctor Payments DataLook up a doctor →

Lander Smith, MD

Family Medicine · Conway, ARNPI 1861479966

Payments from drug & device makers

$16,395in general payments, 2019–2025

Across 1,240 payments — averaging $13.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • AstraZeneca$1K
  • Otsuka America Pharmaceutical, Inc.$932
  • Pfizer$858
  • Lilly USA, LLC$854
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,21799%
  • Education$1781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk125$1,869
GSK203$1,455
AstraZeneca42$1,106
Otsuka America Pharmaceutical, Inc.49$932
Pfizer68$858
Lilly USA, LLC81$854
AbbVie(2 entities)67$807
Abbott55$692
Amarin Pharma, Inc.50$630
Boehringer Ingelheim47$622
Bayer39$574
Astellas Pharma US Inc26$571
Amgen(2 entities)37$562
Johnson & Johnson39$457
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$344
Novartis31$290
Biohaven Pharmaceutical Holding Company Ltd.23$238
Phathom Pharmaceuticals, Inc.20$232
Biohaven Pharmaceuticals, Inc.21$224
Corium, LLC9$213
Esperion Therapeutics, Inc.17$207
Merck18$197
Supernus Pharmaceuticals, Inc.10$183
Antares Pharma, Inc.10$170
Takeda Pharmaceuticals U.S.A., Inc.8$165
Sanofi-aventis U.S. LLC11$157
Teva Pharmaceuticals USA, Inc.12$153
Jazz Pharmaceuticals Inc.8$129
Kowa Pharmaceuticals America, Inc.10$124
Tris Pharma Inc6$109
Exact Sciences7$105
Shield Therapeutics Inc6$104
Boston Scientific4$85
Corcept Therapeutics4$78
Lundbeck LLC4$78
Radius Health, Inc.6$76
Almatica Pharma LLC4$72
Genentech USA, Inc.5$66
Alnylam Pharmaceuticals Inc.3$62
Dexcom, Inc.3$56
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$54
Eisai Inc.3$44
Nestle Healthcare Nutrition Inc.3$43
Halozyme Inc2$35
Collegium Pharmaceutical, Inc.2$35
Mylan Specialty L.p.2$30
Noven Therapeutics, LLC2$29
Shire North American Group Inc2$25
E.r. Squibb & Sons, L.L.C.2$23
Insulet Corporation1$19
Agios Pharmaceuticals, Inc.1$18
Arbor Pharmaceuticals, Inc.1$17
Bausch Health US, LLC1$17
Ironshore Pharmaceuticals Inc.1$16
Baxter Healthcare1$16
Sumitomo Pharma America, Inc.1$15
Globus Medical1$15
Ironwood Pharmaceuticals, Inc1$14
Nevro Corp.1$12
Valeritas, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,395 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$80,432
Medicare patients
304
Services billed
980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban677$223,836
JardianceEmpagliflozin125$74,542
OzempicSemaglutide66$60,971
XareltoRivaroxaban121$41,559
RelistorMethylnaltrexone Bromide12$32,407
Tresiba Flextouch U-100Insulin Degludec48$26,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$25,176
LantusInsulin Glargine,hum.Rec.Anlog180$20,817
LinzessLinaclotide37$20,481
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog67$19,212
TresibaInsulin Degludec47$18,717
EntrestoSacubitril/Valsartan60$17,969
BrilintaTicagrelor63$17,057
CreonLipase/Protease/Amylase16$16,284
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$16,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$858$223,836677 claims
Novo NordiskOzempic, Tresiba, Levemir, Rybelsus$1,869$105,227209 claims
Boehringer IngelheimJardiance, Spiriva Respimat$622$80,664136 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix$1,455$57,240120 claims
Johnson & JohnsonXarelto$457$41,559121 claims
AbbVieLinzess, Creon$807$36,76553 claims
AstraZenecaBrilinta, Breztri Aerosphere, Farxiga$1,106$35,91998 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$344$32,40712 claims
Sanofi-aventis U.S. LLCLantus$157$20,817180 claims
NovartisEntresto$290$17,96960 claims
Astellas Pharma US IncMyrbetriq$571$8,94939 claims
MerckVerquvo$197$7,67624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →